CAS: 200815-49-2; (2R,3R)-2,3-Dihydroxybutanedioic Acid,N-[2-Hydroxy-5-[(1R)-1-Hydroxy-2-[[(2R)-1-(4-Methoxyphenyl)Propan-2-Yl]Amino]Ethyl]Phenyl]Formamide

该化合物是一种主要用于慢性阻塞性肺病(COPD)和哮喘管理的长效乙-2肾上腺激动剂; 气相色谱的R-enantomer the respotero, 提高了其治疗效果; 刺激支气管滑动肌肉乙-2肾上腺受体,导致气相消化和改善空气流; 气相色谱通常通过吸入方式施用,允许直接将其治疗效果送到肺部,从而最大限度地扩大其治疗效果,同时尽量减少系统性副作用; 物质具有相对长的动作,从支气管中持续缓解. 必须指出,虽然气相色谱可改善肺功能,但并非用于立即缓解急性支气管运动,而应用作全面治疗计划的一部分. 与其他乙型激动剂一样, 潜在的副作用可能包括心血管效应, 颤动和...

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-10391166-B2
    优先权日:2013-02-18
    标 题:Short oligonucleotides as vaccine adjuvants and therapeutic agents
    发明人:IYER RADHAKRISHNAN P
    权利人:SPRING BANK PHARMACEUTICALS INC; SPRING BREAK PHARMACEUTICALS INC
    摘要:The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human). The compounds of the invention include, for example, di-, and trinucleotide compounds as provided herein. The compounds of the invention are useful for different therapeutic applications including, such as, prophylactics and therapeutics. The invention also provides design and synthesis of a compound that is useful for various therapeutic applications as mentioned herein.

    专利号:CA-2724882-A1
    优先权日:2008-06-02
    标 题:Process for the synthesis of arformoterol

    专利号:US-2015210629-A1
    优先权日:2008-06-02
    标题 :Process for the Synthesis of Arformoterol

    专利号:AU-2009253877-A1
    优先权日:2008-06-02
    标题:Process for the synthesis of arformoterol

    专利号:AU-2009253877-B2
    优先权日:2008-06-02
    标 题 :Process for the synthesis of arformoterol

    专利号:KR-20110015449-A
    优先权日:2008-06-02
    标题:Process for the synthesis of arformoterol
    天津炜捷制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.weijiegroup.com
    电话: 0086-22-67161625/67161255👤
    📞天津炜捷制药有限公司 ⚠️参考联系方式

    销售电话:0086-22-67161625/67161255
    邮箱:info@weijiegroup.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Cazzola M, Hanania NA, Matera MG. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med. 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16. 5(1):25-7. doi: 10.2165/00126839-200405010-00004. 45(1):3-9. doi: 10.1358/dot.2009.45.1.1313983. 146(6):1531-1542. doi: 10.1378/chest.14-0117.
    5: Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021. Epub 2016 Dec 20. 23(10):2477-83. doi: 10.1185/030079907X233106. 21(4):657-62. doi: 10.1016/j.pupt.2008.03.003. Epub 2008 Apr 7.
    8:631-9. doi: 10.2147/COPD.S52557. Epub 2013 Dec 5.

    合成参考文献


    摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2010).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知